Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin for Postprandial Hyperinsulinemic Hypoglycemia After RYGB
NCT04720859Unknown
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jan 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of canagliflozin in Postprandial hyperinsulinemic hypoglycemia (PHH) (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoints: Response to OGTT in basal conditions and after treatment at 180 minutes, Serum insulin response to OGTT at 180 minutes and 1 more. Status: unknown.
02
Drugs
canagliflozin
03
Conditions
Postprandial hyperinsulinemic hypoglycemia (PHH)
Beyond the preview
Go deeper on NCT04720859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720859.